Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cabaletta Bio, Inc. (CABA : NSDQ)
 
 • Company Description   
Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States.

Number of Employees: 54

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.42 Daily Weekly Monthly
20 Day Moving Average: 171,790 shares
Shares Outstanding: 28.98 (millions)
Market Capitalization: $41.15 (millions)
Beta: 1.53
52 Week High: $14.95
52 Week Low: $1.17
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.97% 16.03%
12 Week -34.86% -26.79%
Year To Date -62.53% -54.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2929 ARCH STREET SUITE 600
-
PHILADELPHIA,PA 19104
USA
ph: 267-759-3100
fax: -
investors@cabalettabio.com http://www.cabalettabio.com
 
 • General Corporate Information   
Officers
Steven Nichtberger - Chairman; Chief Executive Officer and President
Anup Marda - Chief Financial Officer
Catherine Bollard - Director
Scott Brun - Director
Richard Henriques - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 12674W109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 28.98
Most Recent Split Date: (:1)
Beta: 1.53
Market Capitalization: $41.15 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.07 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.33
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -9.76%
vs. Previous Quarter: 8.16%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -44.76
12/31/21 - -42.16
09/30/21 - -38.73
ROA
03/31/22 - -42.19
12/31/21 - -39.97
09/30/21 - -36.95
Current Ratio
03/31/22 - 16.07
12/31/21 - 14.86
09/30/21 - 20.07
Quick Ratio
03/31/22 - 16.07
12/31/21 - 14.86
09/30/21 - 20.07
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 4.26
12/31/21 - 4.16
09/30/21 - 4.12
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©